On demand - The MFN effect: what payers expect and how Pharma should respond

How could Most Favoured Nation (MFN) pricing policies reshape pharmaceutical pricing, market access strategy, and payer decision-making? In this on-demand webinar, market access and healthcare experts explore the potential impact of MFN policies on drug pricing, reimbursement, payer expectations, and the future of pharmaceutical commercialisation. Learn how pharmaceutical companies can prepare for an evolving payer landscape and adapt their evidence generation and market access strategies. Featuring expert speakers: Manca Povsic Omar Ali Kevin Wilson Detlev Patrov This webinar is relevant for professionals working in: Market Access HEOR Pricing & Reimbursement Health Economics Commercial Strategy Medical Affairs Market Research Healthcare Consulting Pharmaceutical and Biotechnology Companies Subscribe for more expert insights on: market access, HEOR, health economics, pharmaceutical strategy, healthcare policy, evidence generation, payer insights and drug pricing Chapter list: 0:00 Introduction and overview 9:10 Current and future impacts of MFN 41:43 Considerations for Pharma 46:07 Audience Q&A 1:00:37 Closing remarks